FLT3LG and lip and oral cavity carcinoma: Since PARPi-FL is currently evaluated in a phase 2 clinical trial for oral cancer detection after topical application, its clinical translation for early detection of dysplasia and EAC in BE patients by allowing a red-flag biopsy protocol via FME could be accelerated.